PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 88 filers reported holding PHATHOM PHARMACEUTICALS INC in Q4 2022. The put-call ratio across all filers is 1.42 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $651,257 | -27.6% | 62,802 | 0.0% | 0.61% | -24.7% |
| Q2 2023 | $899,325 | +100.6% | 62,802 | 0.0% | 0.81% | +90.8% |
| Q1 2023 | $448,406 | -36.4% | 62,802 | 0.0% | 0.42% | -46.0% |
| Q4 2022 | $704,638 | -26.8% | 62,802 | -27.8% | 0.79% | -37.5% |
| Q3 2022 | $963,000 | +31.2% | 86,940 | 0.0% | 1.26% | +27.4% |
| Q2 2022 | $734,000 | -38.0% | 86,940 | 0.0% | 0.99% | -27.9% |
| Q1 2022 | $1,183,000 | -57.6% | 86,940 | 0.0% | 1.37% | -68.9% |
| Q3 2021 | $2,791,000 | -5.2% | 86,940 | 0.0% | 4.41% | +20.0% |
| Q2 2021 | $2,943,000 | -9.9% | 86,940 | 0.0% | 3.68% | -0.3% |
| Q1 2021 | $3,265,000 | +13.1% | 86,940 | 0.0% | 3.69% | +44.6% |
| Q4 2020 | $2,888,000 | -9.4% | 86,940 | 0.0% | 2.55% | -43.3% |
| Q3 2020 | $3,188,000 | +11.4% | 86,940 | 0.0% | 4.50% | +53.8% |
| Q2 2020 | $2,861,000 | – | 86,940 | – | 2.92% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 3,760,869 | $39,000,212 | 12.45% |
| Frazier Life Sciences Management, L.P. | 10,109,279 | $104,833,223 | 6.96% |
| Decheng Capital Management III (Cayman), LLC | 850,000 | $8,814,500 | 2.94% |
| Carlyle Group Inc. | 3,496,808 | $36,191,963 | 1.57% |
| Ghost Tree Capital, LLC | 395,000 | $4,096,150 | 1.35% |
| Newtyn Management, LLC | 500,000 | $5,185,000 | 1.28% |
| Altium Capital Management LP | 220,000 | $2,281,400 | 1.19% |
| StepStone Group LP | 422,085 | $4,377,021 | 0.98% |
| MPM BioImpact LLC | 347,332 | $3,601,833 | 0.96% |
| NEA Management Company, LLC | 1,276,595 | $12,238,290 | 0.94% |